In vitro study of HPV18-positive cervical cancer HeLa cells based on CRISPR/Cas13a system.
Gene
; 921: 148527, 2024 Aug 30.
Article
de En
| MEDLINE
| ID: mdl-38710293
ABSTRACT
The E6 protein is a known oncogene in cervical cancer and plays a key role in the development and progression of cervical cancer by reducing the expression level of the tumor suppressor protein P53 and ultimately leading to enhanced cell proliferation and reduced apoptosis. Therefore, antiviral agents that inhibit the expression of E6 oncoprotein are expected to be potential therapies for human cervical cancer. Here we developed CRISPR/Cas13a crRNA dual plasmid system and demonstrated that CRISPR/Cas13a could effectively and specifically knock down human papillomavirus 18 E6 mRNA, downregulate the expression level of E6 protein, and restore the expression of the tumor suppressor gene P53 protein, thereby inhibiting the growth of cervical cancer cells and increasing their apoptosis, the E6-2, E6-3, and E6-5 groups resulted in apoptosis rates of 25.4%, 22.4%, and 22.2% in HeLa cells. Moreover, CRISPR/Cas13a enhances the proliferation inhibition and apoptosis induction of cisplatin in cervical cancer HeLa cells. The CRISPR/Cas13a system targeting HPV E6 mRNA may be a promising therapeutic approach for the treatment of human papillomavirus-associated cervical cancer.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs du col de l'utérus
/
Protéines des oncogènes viraux
/
Apoptose
/
Prolifération cellulaire
/
Papillomavirus humain de type 18
/
Systèmes CRISPR-Cas
Limites:
Female
/
Humans
Langue:
En
Journal:
Gene
Année:
2024
Type de document:
Article
Pays de publication:
Pays-Bas